Core Viewpoint - The first patient has been treated in the REVISE dose-ranging study by GenSight Biologics in collaboration with the 15-20 National Hospital in Paris, focusing on innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1]. Company Summary - GenSight Biologics is a biopharma company that specializes in developing and commercializing gene therapies aimed at treating retinal neurodegenerative diseases and central nervous system disorders [1]. - The company is listed on Euronext under the ticker SIGHT and is eligible for PEA-PME [1]. Industry Summary - The REVISE study is an open-label, single center trial that aims to enroll patients to evaluate the efficacy of the gene therapy being developed [1].

Core Viewpoint - GenSight Biologics has received authorization from Israel's Ministry of Health for the early access treatment of its gene therapy candidate GS010/LUMEVOQ® for individual patients [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies specifically for retinal neurodegenerative diseases and central nervous system disorders [1]

Core Viewpoint - GenSight Biologics has received compassionate use authorization from the French medicines safety agency ANSM for its innovative gene therapies targeting retinal neurodegenerative diseases and central nervous system disorders [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing gene therapies [1] - The company is listed on Euronext under the ticker SIGHT and is eligible for PEA-PME [1] Regulatory Update - The French medicines safety agency ANSM has granted compassionate use authorization (Autorisation d'Accès Compassionnel, or AA) for GenSight's therapies [1]

Core Insights - GenSight Biologics has received authorization from the French medicines safety agency ANSM to conduct the dose-ranging study REVISE, aimed at investigating the efficacy of its gene therapies for retinal neurodegenerative diseases and central nervous system disorders [1] Company Overview - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies [1] - The company specializes in treatments for retinal neurodegenerative diseases and central nervous system disorders [1]

Core Insights - GenSight Biologics has received regulatory authorizations for its gene therapy GS010/LUMEVOQ® for Individual Patient Expanded Access in the United States [1] Company Summary - GenSight Biologics is a biopharma company focused on developing and commercializing innovative gene therapies specifically for retinal neurodegenerative diseases and central nervous system disorders [1]